MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

- MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of...

Related Keywords

United States ,Chris Chapman ,Drug Administration ,Mymd Pharmaceuticals ,Us Drug Enforcement Administration ,Company Annual Report On Form ,Company Quarterly Reports On Form ,Mymd Pharmaceuticals Inc ,Nasdaq ,United States Food ,Chief Medical Officer ,Enforcement Administration ,Controlled Substances Act ,Annual Report ,Quarterly Reports ,Markets ,